Plant · Scientific monograph
Aesculus hippocastanum
Horse Chestnut
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Venous & Peripheral Circulation, Vascular Health Research
Research overview
Historical use
Horse chestnut seed extracts have been traditionally used for pain, swelling and other complaints. EMA distinguishes specific standardized oral extracts with well-established use in venous insufficiency from traditional oral/topical preparations for minor venous complaints or bruises [3][4].
Modern research context
Standardized horse chestnut seed extracts have been studied for short-term venous-insufficiency symptoms, with larger and longer rigorous trials still needed [1]. A Cochrane review of 17 trials found signals for reduced leg pain and leg volume but emphasized caveats [1][3]. A randomized, partially blinded 12-week trial of 240 adults compared a dried seed extract with compression stockings and placebo; leg-volume findings do not establish prevention of thrombosis or equivalence for every clinical outcome [2]. Provisional archive Level B applies to studied short-term venous symptoms. Raw seeds and other raw parts are toxic and are not the tested preparations [4].
Adverse effects
Standardized oral seed extracts may cause gastrointestinal complaints, headache, vertigo/dizziness, itching or allergic reactions; EMA gives frequency as unknown. Topical preparations may cause skin hypersensitivity [3][4]. Short-term trial tolerability cannot exclude rare or delayed adverse events [1].
Contraindications
Hypersensitivity is an EMA contraindication. Sudden leg swelling, severe pain, thrombophlebitis, ulcers, skin inflammation or possible cardiac/renal insufficiency require medical evaluation rather than self-treatment [3]. Oral venous-use preparations are not recommended below age 18 in the EMA monograph. Raw seed, leaf, bark and flower ingestion must be avoided [3][4]. No validated perioperative washout interval was established.
Clinical and phytochemical data
Used part
Seed-derived standardized extracts used in clinical trials; not raw seeds, bark, leaves or flowers. EMA standardized extracts specify constituent assay and extraction solvent, so older aescin values and newer protoaescigenin-based values should not be casually interchanged [1][3][4].
Primary active compounds
Aescin/escin (mixture of triterpene saponins in standardized seed extracts) [1][2][3]
Mechanism of action
The exact mechanism is unknown. EMA describes preclinical and clinical pharmacological evidence involving venous tone and capillary filtration; these are pharmacological processes rather than established single molecular targets, and symptom evidence does not imply antithrombotic efficacy [3].
Pharmacokinetics
Absorption
Relevant human absorption parameters for the specified whole extract are not supplied by the EMA monograph; formulation-specific bioavailability cannot be inferred from symptom trials [3].
Distribution
Human tissue distribution and protein binding for complete standardized extracts were not established in the selected sources [3].
Metabolism
Complete human metabolic pathways and clinically relevant CYP effects were not established in selected sources [3].
Excretion
Reliable extract-level renal/biliary recovery, half-life and impairment adjustment were not established in the selected sources [3].
Safety and interactions
Drug interactions
EMA reports no interactions for the defined preparations; this is not proof that all products or drug combinations lack interactions. A clinically quantified anticoagulant or CYP interaction was not established in the selected sources, so no severity grade or washout interval is invented [3].
Toxicity
Raw seeds, bark, flowers and leaves contain a toxic component and are unsafe for oral use. NCCIH distinguishes these from standardized seed extracts in which that component has been removed [4]. The evidence concerns short exposures, often no longer than 12 weeks; reproductive, genotoxicity and carcinogenicity testing is incomplete and long-term human toxicity remains uncertain [3][4].
Special precautions
Pregnancy
Pregnancy safety is not established; EMA does not recommend use [3].
Lactation
Milk transfer and infant safety are unknown; EMA does not recommend use during breastfeeding [3].
Hepatic impairment
No validated hepatic-impairment dose adjustment or adequate disease-specific safety data identified; individualized assessment is required [3].
Renal impairment
EMA specifically calls for medical evaluation in renal insufficiency or unexplained leg oedema; no validated renal dosing adjustment is established [3].
Sources and references
- [1] - Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews, 2012. PMID: 23152216. DOI: 10.1002/14651858.cd003230.pub4
- [2] - Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet (London, England), 1996. PMID: 8569363. DOI: 10.1016/s0140-6736(96)90467-5
- [3] - EMA/HMPC. European Union herbal monograph on Aesculus hippocastanum L., semen. Final revision 1, 15 January 2020. https://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-aesculus-hippocastanum-l-semen-final-revision-1_en.pdf
- [4] - NCCIH. Horse Chestnut. Accessed 25 October 2026. https://www.nccih.nih.gov/health/horse-chestnut